Vepugratinib clinical trials
Also written LY3866288.
How each study uses vepugratinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vepugratinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test vepugratinib.
- Jun 2027FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3Phase 1 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses vepugratinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingPhase 1Eli Lilly and CompanyNCT05614739Written as Vepugratinib
- A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial CancerNot yet recruitingPhase 2Eli Lilly and CompanyNCT07827612Written as Vepugratinib
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractRecruitingPhase 3Eli Lilly and CompanyNCT07218380Written as Vepugratinib
- A Study of LY3866288 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06641037Written as LY3866288
- A Study of [14C]-LY3866288 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06644378Written as [14C]-LY3866288
Codes
What other systems call vepugratinib · ClinicalTrials.gg INT017922
- UNII (FDA) SN3C4ZE59PVEPUGRATINIBConfirmed FDA, Wikidata
- Wikidata Q140529352vepugratinibConfirmed FDA, Wikidata
- NCI Thesaurus C192227VepugratinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SN3C4ZE59P | VEPUGRATINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529352 | vepugratinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C192227 | Vepugratinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.